302 related articles for article (PubMed ID: 11292002)
21. Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
O'Malley SS; Todtenkopf MS; Du Y; Ehrich E; Silverman BL
Alcohol Clin Exp Res; 2018 Oct; 42(10):2011-2021. PubMed ID: 30055046
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Johnson BA; Ait-Daoud N; Seneviratne C; Roache JD; Javors MA; Wang XQ; Liu L; Penberthy JK; DiClemente CC; Li MD
Am J Psychiatry; 2011 Mar; 168(3):265-75. PubMed ID: 21247998
[TBL] [Abstract][Full Text] [Related]
23. Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia.
Petrakis IL; O'Malley S; Rounsaville B; Poling J; McHugh-Strong C; Krystal JH;
Psychopharmacology (Berl); 2004 Mar; 172(3):291-7. PubMed ID: 14634716
[TBL] [Abstract][Full Text] [Related]
24. The status of naltrexone in the treatment of alcohol dependence: specific effects on heavy drinking.
Pettinati HM; O'Brien CP; Rabinowitz AR; Wortman SP; Oslin DW; Kampman KM; Dackis CA
J Clin Psychopharmacol; 2006 Dec; 26(6):610-25. PubMed ID: 17110818
[TBL] [Abstract][Full Text] [Related]
25. Experience of a "slip" among alcoholics treated with naltrexone or placebo.
O'Malley SS; Jaffe AJ; Rode S; Rounsaville BJ
Am J Psychiatry; 1996 Feb; 153(2):281-3. PubMed ID: 8561215
[TBL] [Abstract][Full Text] [Related]
26. Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial.
O'Malley SS; Sinha R; Grilo CM; Capone C; Farren CK; McKee SA; Rounsaville BJ; Wu R
Alcohol Clin Exp Res; 2007 Apr; 31(4):625-34. PubMed ID: 17374042
[TBL] [Abstract][Full Text] [Related]
27. Study suggests gene may predict success of therapies for alcohol dependence.
Kuehn BM
JAMA; 2011 Mar; 305(10):984-5. PubMed ID: 21386072
[No Abstract] [Full Text] [Related]
28. Naltrexone modification of drinking effects in a subacute treatment and bar-lab paradigm: influence of OPRM1 and dopamine transporter (SLC6A3) genes.
Anton RF; Voronin KK; Randall PK; Myrick H; Tiffany A
Alcohol Clin Exp Res; 2012 Nov; 36(11):2000-7. PubMed ID: 22551036
[TBL] [Abstract][Full Text] [Related]
29. Predictors of Naltrexone Response in a Randomized Trial: Reward-Related Brain Activation, OPRM1 Genotype, and Smoking Status.
Schacht JP; Randall PK; Latham PK; Voronin KE; Book SW; Myrick H; Anton RF
Neuropsychopharmacology; 2017 Dec; 42(13):2640-2653. PubMed ID: 28409564
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study.
Anton RF; Oroszi G; O'Malley S; Couper D; Swift R; Pettinati H; Goldman D
Arch Gen Psychiatry; 2008 Feb; 65(2):135-44. PubMed ID: 18250251
[TBL] [Abstract][Full Text] [Related]
31. Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial.
Heinälä P; Alho H; Kiianmaa K; Lönnqvist J; Kuoppasalmi K; Sinclair JD
J Clin Psychopharmacol; 2001 Jun; 21(3):287-92. PubMed ID: 11386491
[TBL] [Abstract][Full Text] [Related]
32. Topiramate Versus Naltrexone for Alcohol Use Disorder: A Genotype-Stratified Double-Blind Randomized Controlled Trial.
Morley KC; Kranzler HR; Luquin N; Jamshidi N; Adams C; Montebello M; Tremonti C; Dali G; Logge W; Baillie A; Teesson M; Trent R; Haber PS
Am J Psychiatry; 2024 May; 181(5):403-411. PubMed ID: 38706338
[TBL] [Abstract][Full Text] [Related]
33. Correlation of stable elevations in striatal mu-opioid receptor availability in detoxified alcoholic patients with alcohol craving: a positron emission tomography study using carbon 11-labeled carfentanil.
Heinz A; Reimold M; Wrase J; Hermann D; Croissant B; Mundle G; Dohmen BM; Braus DF; Schumann G; Machulla HJ; Bares R; Mann K
Arch Gen Psychiatry; 2005 Jan; 62(1):57-64. PubMed ID: 15630073
[TBL] [Abstract][Full Text] [Related]
34. The Kappa Opioid Receptor Is Associated With Naltrexone-Induced Reduction of Drinking and Craving.
de Laat B; Goldberg A; Shi J; Tetrault JM; Nabulsi N; Zheng MQ; Najafzadeh S; Gao H; Kapinos M; Ropchan J; O'Malley SS; Huang Y; Morris ED; Krishnan-Sarin S
Biol Psychiatry; 2019 Dec; 86(11):864-871. PubMed ID: 31399255
[TBL] [Abstract][Full Text] [Related]
35. Effects of alcohol availability, access to alcohol, and naltrexone on self-reported craving and patterns of drinking in response to an alcohol-cue availability procedure.
Kruse MI; Radnovich AJ; Kalapatapu RK; Mehdiyoun N; Chambers RA; Davidson D
J Stud Alcohol Drugs; 2012 Mar; 73(2):205-15. PubMed ID: 22333328
[TBL] [Abstract][Full Text] [Related]
36. Effect of naltrexone on alcohol "high" in alcoholics.
Volpicelli JR; Watson NT; King AC; Sherman CE; O'Brien CP
Am J Psychiatry; 1995 Apr; 152(4):613-5. PubMed ID: 7694913
[TBL] [Abstract][Full Text] [Related]
37. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism.
Anton RF; Moak DH; Latham PK; Waid LR; Malcolm RJ; Dias JK; Roberts JS
J Clin Psychopharmacol; 2001 Feb; 21(1):72-7. PubMed ID: 11199951
[TBL] [Abstract][Full Text] [Related]
38. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.
Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA;
Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315
[TBL] [Abstract][Full Text] [Related]
39. Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.
Martinotti G; Di Nicola M; Di Giannantonio M; Janiri L
J Psychopharmacol; 2009 Mar; 23(2):123-9. PubMed ID: 18515460
[TBL] [Abstract][Full Text] [Related]
40. Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial.
Foa EB; Yusko DA; McLean CP; Suvak MK; Bux DA; Oslin D; O'Brien CP; Imms P; Riggs DS; Volpicelli J
JAMA; 2013 Aug; 310(5):488-95. PubMed ID: 23925619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
